Ubiquitination and degradation of ribonucleotide reductase M1 by the polycomb group proteins RNF2 and Bmi1 and cellular response to gemcitabine.
Ribonucleotide reductase M1 (RRM1) is required for mammalian deoxyribonucleotide (dNTP) metabolism. It is the primary target of the antimetabolite drug gemcitabine, which is among the most efficacious and most widely used cancer therapeutics. Gemcitabine directly binds to RRM1 and irreversibly inact...
Saved in:
Main Authors: | Yingtao Zhang, Xin Li, Zhengming Chen, Gerold Bepler |
---|---|
Format: | article |
Language: | EN |
Published: |
Public Library of Science (PLoS)
2014
|
Subjects: | |
Online Access: | https://doaj.org/article/baf60fec75ac48fea5e00121a55b4879 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy.
by: Jun Zhou, et al.
Published: (2013) -
Convergent allostery in ribonucleotide reductase
by: William C. Thomas, et al.
Published: (2019) -
RNF167 activates mTORC1 and promotes tumorigenesis by targeting CASTOR1 for ubiquitination and degradation
by: Tingting Li, et al.
Published: (2021) -
Acetylation regulates ribonucleotide reductase activity and cancer cell growth
by: Guo Chen, et al.
Published: (2019) -
Biofilm modifies expression of ribonucleotide reductase genes in Escherichia coli.
by: Maria del Mar Cendra, et al.
Published: (2012)